Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Presentation TCT 2019

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

Presenter: yoichiro sugizaki

September 25, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Shelley Wood

February 12, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Advertisement

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Recurrent Events Common Among Young Patients With CAD

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content